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The present manuscript focuses on a putative natriuretic hormone. It includes the history
of a long-term search for the pure molecule, ranging from partial purification to synthesis. It
includes a description of seven different bioassay systems used, a resume of the sequen-
tial steps in purification, and a summary of a series of experimental protocols employed
in the effort to define the biologic properties of the inhibitor of sodium (Na) transport. Two
closely related molecules were purified and synthesized. Both are xanthurenic acid deriva-
tives (xanthurenic acid 8-O-β-D-glucoside and xanthurenic acid 8-O-sulfate). It is concluded
that one or both of these two low molecular weight compounds (MW: 368 and 284) meet
many of the criteria for the final modulator of Na excretion.
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INTRODUCTION
It is our assumption that there is a single natriuretic hormone that
serves to modulate the renal excretion of sodium (Na) so as to
preserve an ongoing equality between consecutive 24 h Na excre-
tion by the kidneys and the contemporaneous intake of Na. The
focus on what we presume to be a hormone was initiated from
the classic experiments of DeWardener et al. (1–3). The present
symposium provides a contemporary review of the state-of-the-
art of natriuretic hormone research by key investigators who have
pursued the identity and biologic properties of several different
putative natriuretic hormones.
Because of the design of DeWardener’s protocol, it appeared
likely that all of the factors then known to affect the renal excre-
tion of Na could be excluded as the definitive control element.
These included changes in glomerular filtration rate (GFR) (so-
called “first factor”) and changes in mineralocorticoid hormone
activity (“second factor”). We coined the term “third factor” (4),
which subsequently was replaced by “natriuretic factor.”
Throughout a long period of time, a multinational group of
investigators has sought to isolate and characterize the natriuretic
hormone. To this point in time, despite considerable progress, the
ultimate goal remains elusive. Hence, the present symposium.
Our interest in an endogenous natriuretic hormone arose out
of long-term studies on the pathologic physiology of chronic pro-
gressive renal disease (CRD) (5). It was the pattern of Na excretion
that evolved as nephron destruction proceeded.
What is a remarkable change in the estimated Na excretion rate
per nephron from the beginning to the end of CRD is presented
in Table 1. In constructing this table, the intake of Na per 24 h
was maintained constant (e.g., at 120 mEq/day) and at all levels of
GFR, external Na balance was preserved (the latter is not unusual
down to a GFR as low as 10% of normal.).
At a normal GFR of 120 ml/min in an 80 kg person, Na balance
is achieved by the excretion of 1/2 of 1% of the filtered load of
Na. A fall in GFR to 60 ml/min mandates the excretion of 1% of
the filtered Na. A further reduction of GFR (to 30 ml/min) due to
the progression of the underlying renal disease requires the excre-
tion of 2% of the filtered Na. And at a GFR of 15 ml/min, external
Na balance is achieved by the excretion of 4% of the filtered Na.
Thus, per unit of Na entering the extracellular fluid on a con-
stant Na intake, the excretion rate per milliliter of residual GFR
with no time delay increases by eightfold. Finally, in many forms
of CRD, single nephron GFR (SNGFR) doubles as nephron loss
advances. Na excretion rate per residual nephron per milliequiv-
alents of Na intake, approaches 16 times the value in the normal
subject.
BIOASSAY SYSTEMS
Seven different bioassay systems were used in both the sequential
steps in the isolation, purification, and synthesis of NH and the
studies of the biologic effects of the test materials. Each assay sys-
tem allowed for a quantitative measure of the inhibitory effects of
a test sample on Na transport either in vitro or in vivo.
The primary in vitro systems (frog skin and toad bladder) (6,
7) involve polar epithelial cells that transport Na from the serosal
surface of the membrane across the mucosal surface. Na trans-
port is quantified by the short-circuit current across the isolated
membrane (in an Ussing chamber). Activity of partially purified
to pure NH was detectable only when the inhibitor was added to
the serosal surface of the membrane.
In micropuncture studies (8), isolated cortical collecting
tubules, dissected from normal rabbits were perfused with par-
tially purified test material from the urine of uremic patients. The
perfusate was delivered into the lumen of each nephron segment
and the peritubular surface was bathed in a solution of known
composition (see Experimental Data).
The in vivo assays were performed in rats (9). The test materials
were delivered intravenously, intraarterially, or via a gastric tube.
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Table 1 | Adaptation in Na excretion per nephron in advancing CRD on
a constant salt intake.
GFR
ml/
mn
Na in
mEq/
day
Na out
mEq/
day
µl SNGFR
% of
normal
Na out
per nephron
nEq
Magnification
per nephron
120 120 120 100 700 1
60 120 120 1,400 2
30 120 120 2,800 4
15 120 120 200 5,600 8
7 1/2 120 120 11,212 16
See text in reference to the increase in SNGFR. Column 6 depicts the exponential
increase in sodium excretion per nephron per unit of sodium intake.
In the rat assay, the rats employed had: (1) two normal kid-
neys; (2) one remnant kidney (75% reduction of renal mass) and
a contralateral normal kidney; or (3) a solitary remnant kidney
following removal of the normal kidney.
PURIFICATION OF NH
Twenty-four hour collections of urine were reduced from their
original volume to approximately 20 ml of sludge by lyophiliza-
tion. The sludge was then redissolved in isotonic saline to 25 ml
components each equal to 6 h of original urine. Each sam-
ple then was chromatographed through Sephadex G-25 with
online monitoring of UV absorption at 290 nm and electrical
conductivity (10).
Biologic activity was limited to the “post-salt” peaks using the
frog skin assay (11). Short-circuit current decreased from 40–50 to
20–30µAmp/cm2. These samples were purified using high perfor-
mance liquid chromatography (HPLC) runs. The active fractions
were purified further by two consecutive HPLC runs. The eluate
was monitored by fluorescence and UV absorbance.
After further concentration, a bioassay was performed by infu-
sion of the test material into the uremic rat (11). A strong and
sustained natriuresis was recorded.
The natriuretic fractions, consistently showed two peaks with
strong fluorescence (excitation 332 nm; emission 430 nm) and
characteristic UV absorption (UV max at 338 nm). These spectro-
scopic signatures were used as the main pooling criteria for further
HPLC-based purification of NH (11). Additional steps in isola-
tion, purification, and synthesis of the two molecules: xanthurenic
acid 8-O-β-D-glucoside and xanthurenic acid 8-O-sulfate are
described in a separate publication (11).
EXPERIMENTAL DATA
UREMIC VS. CONTROL SUBJECTS
Based on the adaptation in Na excretion in advancing CRD (see
Table 1), bioassays were performed on normal rats using par-
tially purified urine samples from 17 patients with advanced CRD
(mean GFR 8.7 ml/min) and 14 normal control subjects. The
assays from the normal subjects were negative [i.e., no significant
increase in either absolute Na excretion (UNaV), or the fraction of
filtered Na excreted (FENa) (12)]. The uremic fractions produced a
highly significant increase from baseline levels in both parameters
of Na excretion. With more concentrated samples of the uremic
urine fractions, values for ∆FENa rose to levels as high as 12%.
ADVANCED CRD WITH A SUPERIMPOSED EDEMA-FORMING STATE:
(THE NEPHROTIC SYNDROME)
Eight patients with advanced CRD and the nephrotic syndrome
were studied (12). Assays were performed on normal rats using
partially purified fractions of serum in all eight studies. Fractions
of urine were also used in three studies. Values for UNaV decreased
from control levels (by an average of 0.97µEq/min). The mean
value for FENa also decreased (1.35%).
Danovitch et al. (13) studied a group of five patients with
far advanced CRD (GFR 5.2–16.0 ml/min) who initially were in
Na balance on controlled metabolic diets containing from 58 to
342 mEq of Na per day. In each patient, while under close obser-
vation (clinical and laboratory), the Na content of the diet was
reduced at intervals of 1 week or longer over 4–14 weeks. Four
of the patients exhibited a salt-losing state, wherein Na excretion
exceeded Na intake. Two of these patients required intravenous salt
replacement. At the completion of the studies, all patients main-
tained external Na balance while ingesting a mean of 5.0± 2.9 mEq
of Na/day. Thus, in contrast to patients with advancing CRD who
maintain Na balance on a constant salt intake and a progressively
decreasing nephron population, these patients were subjected to a
progressive reduction of Na intake with an unchanging nephron
population. (GFR remained constant throughout the studies.) The
adaptive increase in Na excretion in advancing CRD (Table 1),
thus was reversed with slow (and cautious) serial reductions in
salt intake. The salt-losing tendency of CRD was reversed.
MICROPUNCTURE STUDIES
As described under Bioassay Systems, partially purified natriuretic
factor was infused into the lumen of isolated cortical collecting
tubules of normal rabbits. No effect was observed with intralumi-
nal infusions. However, when the natriuretic material was added
to the solution bathing the peritubular surface, the effects were
rapid in onset and highly significant. Net Na flux (measured iso-
topically) from luminar to peritubular surface of the nephrons,
decreased from 6.29 to 3.20 pmol/s (p< 0.001) with no change in
Na flux in the opposite direction. Potential difference rose rapidly
from −22.5 to −12 mV. Control studies, using the same fraction
from normal subjects, had no effect (8).
STUDIES ON NORMAL HUMAN BEINGS EXPOSED TO WATER
IMMERSION
Epstein et al. (14) have established water immersion to the neck as
a reliable and reproducible stimulus evoking natriuresis in normal
subjects. The experiments were performed on 12 normal adults
(15). Each was studied twice – once under control conditions sit-
ting in a chair and again during water immersion. The paired
studies were performed at the same time of day. Partially purified
urine samples were assayed for natriuretic activity in normal rats.
UNaV and FENa did not change from the baseline values
in the control studies. During water immersion UNaV rose
(1.27± 0.28µEq/min) and FENa increased from pre-immersion
baseline values by 1.29± 0.21%. Both changes were highly signif-
icant (p< 0.001) (15).
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STUDIES IN DOGS
Normal dogs were maintained on a Na intake varying from 3 to
258 mEq/day, with and without fludrocortisone. Urine was par-
tially purified and assayed for natriuretic effect in normal rats
and for inhibition of Na transport in isolated toad bladders. In
dogs on the 258 mEq Na diet and 0.2 mg fludrocortisone/day,
both a statistically significant natriuretic response and inhibition
of short-circuit current (p< 0.001) were observed. In dogs fed
3 mEq of Na per day with fludrocortisone, no significant effect
was found in either assay system (16).
END-ORGAN RESPONSIVENESS
The effects of nephron loss on the natriuretic response (9) to par-
tially purified natriuretic factor were studied in three groups of
rats, each on a normal salt diet.
1. Group 1: normal rats: intraarterial infusion into one renal
artery produced a unilateral natriuresis.
2. Group 2: intraarterial infusion into the renal artery of a unilat-
eral remnant kidney in rats with a contralateral normal kidney
produced an increase in FENa, which was equal bilaterally.
Intravenous infusion of the natriuretic fraction also produced
comparable increments of FENa in the remnant and the normal
kidneys.
3. Group 3: in uremic rats with a solitary remnant kidney (no con-
tralateral kidney), the intraarterial infusion of natriuretic factor
produced an increase in FENa that was significantly greater
than in remnant kidneys of group 2 rats or normal kidneys
of group 1.
NATRIURETIC RESPONSE TO SYNTHESIZED (PURE) NH
Synthesized preparations of xanthurenic acid 8-O-β-D-glucoside
(NH) and xanthurenic acid 8-O-sulfate (NH-1) were bioassayed
in normal rats (11).
The intravenous infusion of NH (range 0.14–16.4 nmol)
and NH-1 (0.7–4.21 nmol) was studied in eight and five nor-
mal rats, respectively. In the NH group, ∆UNaV averaged
3.68± 0.55µEq/min; in the five experiments in which NH-1 was
the test substance,∆UNaV averaged 4.33± 0.71µEq/min (1).
In five additional studies, a combination of NH (1.4–3.41 nmol)
and NH-1 (1.75–5.44 nmol) was assayed. ∆UNaV averaged
5.0± 0.89µEq/min.
STUDIES BY HOFFMAN AND ASSOCIATES
In a recent publication, Hoffman et al. (17) studied the effects of
xanthurenic acid 8-O-β-D-glucoside on Na excretion in adult male
Sprague-Dawley rats. Each rat was given two consecutive incre-
mental doses (6.3+ 31.5 nmol) of NH (designated as XAG).Values
for ∆UNaV were 3.21± 1.12 and 3.99± 0.95 at the two dosages,
respectively. Values for∆FENa increased significantly (1.63± 0.46)
during the second dose of XAG.
In these studies, GFR (inulin clearance) remained unchanged.
Mean arterial pressure (MAP) and total renal blood flow were
recorded electronically every 5 min for 60 s during the control
periods and for 30–40 min periods during the XAG infusions. All
hemodynamic values remained stable (17).
Two important new observations were made by Hoffman and
coworkers:
1. In rats pretreated with amiloride, an inhibitor of ENaC, the
epithelial Na channel in the distal tubule, the natriuretic effects
of XAG were completely abolished (17).
2. In rats subjected to chronic blockade of the NO system, the
natriuretic response to XAG was diminished suggesting to these
investigators that the renal effects of XAG could be mediated in
part by activation of the renal NO system (17).
DISCUSSION
A large number of factors, both humoral and physical are known
to influence the renal tubular transport of Na. But none of these,
including changes in GFR or mineralocorticoid hormone activity
(see Introduction) is believed to be the final modulator of net Na
transport and thus of Na excretion. We believe that natriuretic hor-
mone fulfills this role. It thus would serve as the definitive element
of a sophisticated biologic control system that is charged with the
preservation of Na balance and with the constancy of the extra-
cellular fluid volume. But, while there may be virtual unanimity
of opinion about the existence of natriuretic hormone, there is no
such unanimity about the nature of this hormone.
In this manuscript, we have reviewed the properties of a natri-
uretic factor, which we have pursued for a long period of time.
The activity was obtained from both serum (or plasma) and urine
using material that ranged from partially purified to pure, chemi-
cally synthesized molecules (11). We believe that the experimental
data reviewed in the manuscript meet at least some of the criteria
for natriuretic hormone. These include:
1. The rapid and reversible inhibition of net Na transport across
polar epithelial cell systems, including the distal portion of the
nephron.
2. The foregoing biologic activity is present only when the
inhibitor is added to the peritubular surface of the nephron
or the serosal surface of equivalent in vitro models.
3. The natriuretic effect of the purified and synthesized material
is completely blocked by prior administration of amiloride, an
inhibitor of ENaC activity in the distal portion of the nephron.
The mechanism of this action could relate either to a direct
effect on the number and/or the activity of ENaC channels,
or to a change in the relation between open vs. closed ENaC
channels.
4. Inhibition of Na transport in the distal nephron associated
with a rapid shift in transepithelial electric potential difference
(i.e., a less negative intraluminal potential).
This change would favor the excretion of Cl with Na as
opposed to increased secretion of K.
5. No evidence for a fixed coupling ratio between the inhibition
of Na transport and K secretion.
6. Increase in natriuretic activity in advancing CRD in purified
serum or urine samples.
7. An increase in end-organ responsivity to the inhibitor associ-
ated with nephron loss.
8. Lack of natriuretic effect of the inhibitor in patients with
advanced CRD and a superimposed edema-forming state (the
nephrotic syndrome).
9. Reversal of salt-losing state in advanced CRD by progressive
slow reduction of salt intake to very low levels.
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Table 2 | A comparison of several natriuretic substances.
Ouabain (OLS) Marinobufogenin
(MFG)
Vanadium
diascorbate
(VD)
Atrial natriuretic peptides Xanthurenic acid
8-O-β-D-glucoside
(XAG)
ANP BNP CNP
Isolation Plasma and
adrenal cortex
and
hypothalamus
(18–23)
Plasma, urine,
and adrenal
cortex (24, 25)
Urine and plasma
(26)
Atria, heart, and
kidney (27)
Brain,
heart, and
kidney (27)
Brain, heart,
and
vasculature
(27, 28)
Plasma and urine
from uremic patients
(6, 8, 10, 29)
Stimulus AII, ACTH, ↑BP
positive sodium
balance or intake;
↑ serum K+ up to
5 mEq/l
Same as OLS Salt loading,
aldosteronism,
and volume
expansion (26)
Stretch of cardiac
wall – especially
the atria, ET
adrenergic stimuli
(30)
Same as
ANP (30)
Same? as
ANP (30)
Normal and uremic
patients and animals
(10, 15)
M.W. 584.6 (31) 387? 600? (31) 403 2,000–3,000±
(32)
2,000–
3,000±
(32)
2,000–
3,000±
(32)
368 (glucoside) 284
(sulfate) (11)
Structure Steroid (31) Steroid (31) Vanadate
diascorbate from
ascorbic acid (26)
28 AA (32) 32 AA (32) 22 AA (32) 8-O-(-D-glucoside
8-O-sulfate of
xanthurenic acid
from tryptophan (11)
Site of Action α2α3 NaK ATPase
primarily (18–23,
25, 26, 33–43)
acts on
basolateral
membrane of
PCT and NHE3 in
PCT (36, 37)
α1 NaK ATPase in
PCT (24, 44)
NaK ATPase in
PCT acts on
basolateral
membrane(26)
Blocks ENaC, ↑
GFR, blocks NaK
ATPase AII in PCT
(30, 45, 46) ↓
H2O absorption in
CT, ↓ urine
concentration (47,
48)
Similar to
ANP
Direct
vasodilator
and simulator
to ANP (47)
Blocks ENaC acts
from basolateral
surface (17)
Natriuresis Variable from no
natriuresis to mild
natriuresis (21,
25, 33, 36, 38,
39)No effect on
α1-NaK ATPase
Variable
natriuresis (24,
44)
Moderate
natriuresis (26)
Moderate
through CGMP
(28, 30, 32, 46)
Same as
ANP(28, 30,
32, 46, 49)
None (28, 47) Eliminated by
blocking ENaC (17)
RBF ↓ (40) ? ? ↑ RBF→ ↑ GFR
(30, 45, 50)
Variable (50) No No effect (17)
GFR ↓ Or no change
(40)
? ? ↑ GFR dilates
afferent arteriole
and constricts
efferent (49)
Same as
ANP (49)
No No effect (17)
K excretion ↓ ↓ ↓ ↑ ↑ ↑ Minimal (11)
Vasoactivity ↑ BP,
vasoconstriction
(21, 22, 33, 34,
36, 40–43) ↑ Ca
influx and Na
influx into vessel
wall (22, 34,
42–44)
↑ BP,
vasoconstriction
(24, 44)
↑ BP (27) ↑ Ca
and Na influx into
vessel wall (25,
27)
↓ BP (32, 47) ↓ BP (32,
47)
? None (17)
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10. Presence of natriuretic activity in urine of normal subjects
during water immersion – an experience known to produce
central hypervolemia.
11. Increased natriuretic activity in normal dogs on a high salt
diet and superimposed mineralocorticoid hormone.
12. No natriuretic activity in normal dogs on a low salt diet and
superimposed mineralocorticoid hormone.
OTHER “NATRIURETIC” FACTORS
Four other categories of putative natriuretic hormones are con-
sidered in separate papers in this symposium. These compounds
include: (1) ouabain [or ouabain-like substances (OLS)]; (2) mari-
nobufogenin (MFG); (3) vanadium diascorbate (VD); and atrial
natriuretic peptides (ANP).
A summary of key properties of each is shown in Table 2 and a
brief description of some relevant characteristics follows.
OUABAIN (OLS)
A small molecule (MW 584.6) isolated from plasma (18), urine,
adrenal cortex, and hypothalamus (19–23). The primary and rele-
vant effects are the inhibition of NaK ATPase and the cross reaction
with ouabain antibodies (21).
But they are inconsistently natriuretic (21, 22, 33, 34), presum-
ably because ouabain has little effect on the α1 subunit of NaK
ATPase (22, 35). Indeed, there also recent evidence that OLS may
actually cause Na retention (26).
MARINOBUFOGENIN
Also a small molecule (MW between 387 and 600) (31), which is
isolated from plasma, urine, and the adrenal cortex (24, 44). No
studies have shown that administration of MFG causes natriuresis
in assay animals. However, administration of anti-MBG antibod-
ies reduces Na excretion (24, 44). Exogenous administration of
bufalin, a very closely related compound, injected into the renal
artery of sheep has been shown to produce natriuresis. No similar
studies have as yet been published using MFG (51).
VANADIUM DIASCORBATE
A small molecule (MW 403) isolated from plasma and urine (26).
Inhibits NaK ATPase in the proximal convoluted tubule. Produces
moderate natriuresis, may produce influx of Ca++ into vessel walls
and thereby increase BP.
ATRIAL NATRIURETIC PEPTIDES
Molecular weight 2,000–3,000± (32). The natriuretic peptides,
while producing natriuresis, also increase GFR and increase
glomerular pressure by dilating the afferent arteriole, and con-
stricting the efferent arteriole (30, 45, 50). It may cause progressive
renal failure in animal models.
If ANP is the final modulator of Na balance, there is a para-
dox. In advanced cirrhosis, there is an increase in preload and a
decrease in central volume and EAV. ANP levels are elevated (50).
Likewise in CHF there is a decrease in EAV and an increase in
preload and again ANP levels are elevated. Physiologically both
situations should invoke Na retention due to the decrease in the
EAV, which in turn should shut off natriuresis, but in both of these
situations ANP is elevated.
The arterial natriuretic peptides are primarily vasoactive and
act on multiple sites of the nephron including the proximal tubule.
CONCLUSION
The cumulative data presented in this paper lend support to the
view that xanthurenic acid 8-O-β-D-glucoside and xanthurenic
acid 8-O-sulfate could be the long sought after and elusive natri-
uretic hormone. But to validate, or refute this thesis, additional
experimental evidence is required. A partial list of key areas of
future study includes:
1. A sensitive assay system for quantifying the levels of the putative
hormone in body fluids.
2. Establishing the site of production.
3. The character of the signaling process (including the nature
of the receptors), involved in initiating and controlling the
induced natriuresis.
4. The enzymes involved in the synthesis.
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